Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Stanley T. Crooke sold 11,000 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $55.35, for a total value of $608,850.00. Following the transaction, the chairman now owns 48,014 shares in the company, valued at approximately $2,657,574.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) traded down 0.36% during midday trading on Friday, hitting $46.98. The company had a trading volume of 673,205 shares. The stock’s 50-day moving average price is $51.56 and its 200-day moving average price is $47.09. Ionis Pharmaceuticals, Inc. has a 52-week low of $24.58 and a 52-week high of $60.01. The stock has a market cap of $5.84 billion, a PE ratio of 225.87 and a beta of 3.14.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.03. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The business had revenue of $104.15 million for the quarter, compared to analysts’ expectations of $93.29 million. During the same period in the prior year, the company earned ($0.47) EPS. The company’s revenue for the quarter was up 170.7% compared to the same quarter last year. On average, equities research analysts expect that Ionis Pharmaceuticals, Inc. will post ($0.20) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Stanley T. Crooke Sells 11,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/08/19/ionis-pharmaceuticals-inc-ions-chairman-sells-608850-00-in-stock-updated-updated-updated.html.
A number of brokerages have issued reports on IONS. BMO Capital Markets reiterated an “outperform” rating and set a $59.00 price target on shares of Ionis Pharmaceuticals in a research report on Wednesday, April 26th. Stifel Nicolaus increased their price target on Ionis Pharmaceuticals from $42.00 to $50.00 and gave the stock a “hold” rating in a research report on Wednesday, August 9th. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Wednesday, July 5th. Leerink Swann restated an “outperform” rating and issued a $45.00 target price (down previously from $47.00) on shares of Ionis Pharmaceuticals in a research report on Wednesday, May 17th. Finally, Needham & Company LLC restated a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a research report on Wednesday, July 26th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Ionis Pharmaceuticals has an average rating of “Hold” and an average target price of $48.91.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new position in shares of Ionis Pharmaceuticals during the fourth quarter worth $976,000. Comerica Bank increased its stake in Ionis Pharmaceuticals by 33.3% in the fourth quarter. Comerica Bank now owns 16,505 shares of the company’s stock worth $794,000 after buying an additional 4,122 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Ionis Pharmaceuticals by 361.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 97,341 shares of the company’s stock worth $4,656,000 after buying an additional 76,259 shares during the last quarter. Teachers Advisors LLC increased its stake in Ionis Pharmaceuticals by 14.7% in the fourth quarter. Teachers Advisors LLC now owns 123,810 shares of the company’s stock worth $5,922,000 after buying an additional 15,904 shares during the last quarter. Finally, Opus Point Partners Management LLC increased its stake in Ionis Pharmaceuticals by 1.5% in the fourth quarter. Opus Point Partners Management LLC now owns 77,550 shares of the company’s stock worth $3,709,000 after buying an additional 1,111 shares during the last quarter. 89.08% of the stock is currently owned by institutional investors.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
What are top analysts saying about Ionis Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ionis Pharmaceuticals Inc. and related companies.